Literature DB >> 31091976

Treatment of Neurodegenerative Diseases with Bioactive Components of Tripterygium wilfordii.

Jianheng Li1, Jijun Hao2,3.   

Abstract

Tripterygium wilfordii Hook F. (TWHF), a traditional Chinese medicine, has been widely used to treat autoimmune and inflammatory diseases including rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis in China. Recently, studies have demonstrated that the bioactive components of TWHF have effective therapeutic potential for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and Multiple Sclerosis. In this paper, we summarize the research progress of triptolide and celastrol (the two major TWHF components) as well as their analogues in the treatment of neurodegenerative diseases. In addition, we review and discuss the molecular mechanisms and structure features of those two bioactive TWHF components, highlighting their therapeutic promise in neurodegenerative diseases.

Entities:  

Keywords:  Alzheimer’s Disease; Celastrol; Central Nervous System; Parkinson’s Disease; Review; Triptolide

Mesh:

Substances:

Year:  2019        PMID: 31091976     DOI: 10.1142/S0192415X1950040X

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  9 in total

1.  Comparative transcriptomics and network pharmacology analysis to identify the potential mechanism of celastrol against osteoarthritis.

Authors:  Siming Dai; Hui Wang; Meng Wang; Yue Zhang; Zhiyi Zhang; Zhiguo Lin
Journal:  Clin Rheumatol       Date:  2021-04-19       Impact factor: 2.980

Review 2.  Neuroprotective Effects of Celastrol in Neurodegenerative Diseases-Unscramble Its Major Mechanisms of Action and Targets.

Authors:  Dandan Liu; Qian Zhang; Piao Luo; Liwei Gu; Shengnan Shen; Huan Tang; Ying Zhang; Ming Lyu; Qiaoli Shi; Chuanbin Yang; Jigang Wang
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968

Review 3.  Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application.

Authors:  Jinfeng Shi; Jiaxin Li; Ziyi Xu; Liang Chen; Ruifeng Luo; Chen Zhang; Fei Gao; Jinming Zhang; Chaomei Fu
Journal:  Front Pharmacol       Date:  2020-11-18       Impact factor: 5.810

4.  Identifying the Effect of Celastrol Against Ovarian Cancer With Network Pharmacology and In Vitro Experiments.

Authors:  Xuan Wang; Qiong Liu; Sisi Wu; Nana Xu; Hua Li; Aihua Feng
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

5.  Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion.

Authors:  Carlos A Fuzo; Ronaldo B Martins; Thais F C Fraga-Silva; Martin K Amstalden; Thais Canassa De Leo; Juliano P Souza; Thais M Lima; Lucia H Faccioli; Débora Noma Okamoto; Maria Aparecida Juliano; Suzelei C França; Luiz Juliano; Vania L D Bonato; Eurico Arruda; Marcelo Dias-Baruffi
Journal:  Drug Dev Res       Date:  2022-08-21       Impact factor: 5.004

Review 6.  Triptolide: pharmacological spectrum, biosynthesis, chemical synthesis and derivatives.

Authors:  Jie Gao; Yifeng Zhang; Xihong Liu; Xiayi Wu; Luqi Huang; Wei Gao
Journal:  Theranostics       Date:  2021-05-24       Impact factor: 11.556

Review 7.  Treatment of tibial dyschondroplasia with traditional Chinese medicines: "Lesson and future directions".

Authors:  Hui Zhang; Yajing Wang; Khalid Mehmood; Yung-Fu Chang; Zhaoxin Tang; Ying Li
Journal:  Poult Sci       Date:  2020-09-08       Impact factor: 3.352

Review 8.  Treatment of Glaucoma with Natural Products and Their Mechanism of Action: An Update.

Authors:  Ru Hui Sim; Srinivasa Rao Sirasanagandla; Srijit Das; Seong Lin Teoh
Journal:  Nutrients       Date:  2022-01-26       Impact factor: 5.717

9.  Celastrol exerts a neuroprotective effect by directly binding to HMGB1 protein in cerebral ischemia-reperfusion.

Authors:  Dan-Dan Liu; Piao Luo; Liwei Gu; Qian Zhang; Peng Gao; Yongping Zhu; Xiao Chen; Qiuyan Guo; Junzhe Zhang; Nan Ma; Jigang Wang
Journal:  J Neuroinflammation       Date:  2021-08-09       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.